ABBV vs JNJ: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Johnson & Johnson — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-15.
AbbVie Inc. · Healthcare
$261.07
+1.2% upside to fair value
Grade C
High Quality
VS
Johnson & Johnson · Healthcare
$253.85
-21.7% upside to fair value
Grade D
High Quality
QuantHub Verdict
ABBV has more upside to fair value
(+1.2%).
JNJ trades at a lower forward P/E
(29.3x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
JNJ |
| Current Price |
$261.07 |
$253.85 |
| Fair Value Estimate |
$264.30 |
$198.76 |
| Upside to Fair Value |
+1.2%
|
-21.7%
|
| Market Cap |
$461.3B |
$611.1B |
| Forward P/E |
128.0x
|
29.3x
|
| EV / EBITDA |
31.0x
|
19.2x
|
| Price / Sales |
7.3x
|
6.3x
|
| Price / FCF |
22.1x
|
34.3x
|
| Revenue Growth YoY |
+12.4%
|
+9.9%
|
| Gross Margin |
70.7%
|
69.1%
|
| Operating Margin |
27.6%
|
26.9%
|
| Return on Equity |
68.0%
|
26.3%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
4.52%
|
2.91%
|
| Analyst Consensus |
Strong Buy
|
Buy
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology and aesthetics. The company is transitioning from its historical Humira dominance, which has faced loss of exclusivity, toward high-growth assets like Skyrizi and Rinvoq that are driving robust revenue growth of 12.4% in the most recent quarter. Despite strong revenue growth and a dura…
Johnson & Johnson is a leading healthcare conglomerate operating primarily in the drug manufacturing sector, known for its durable competitive moat supported by strong brand recognition and intangible assets. The company exhibits high business quality with a 26.3% return on equity and robust gross and net margins of 69.1% and 21.8%, respectively. However, earnings have faced significant pressure,…
Accumulation Zones
| Metric |
ABBV |
JNJ |
| Zone Low |
$198.23 |
$149.07 |
| Zone High |
$224.66 |
$168.95 |
| In Buy Zone? |
No
|
No
|